Genmab A/S is a Danish biotechnology company focused on the discovery and development of antibody-based therapeutics, primarily for oncology and immune-related diseases. Headquartered in Copenhagen, with operations in Europe, North America, and Asia, the company advances monoclonal and bispecific antibody technologies through in-house research and collaborations. Related entities include Genmab Holding II B.V. and Genmab Finance LLC.
Genmab’s business model centers on proprietary antibody engineering platforms, co-development agreements, and licensing, generating revenue from research funding, milestones, and royalties. Antibodies discovered or developed by Genmab and commercialized with partners include daratumumab (marketed by Janssen, a Johnson & Johnson company, for multiple myeloma), epcoritamab (co-developed and co-commercialized with AbbVie for B-cell lymphomas), tisotumab vedotin (with Seagen for recurrent or metastatic cervical cancer), amivantamab (marketed by Janssen for certain EGFR-mutated lung cancers), and ofatumumab (licensed to Novartis, marketed as Kesimpta for multiple sclerosis). Genmab continues to expand its pipeline across hematologic malignancies and solid tumors through clinical trials and partnerships.
To provide comprehensive coverage, we aggregate data and news under the name Genmab, encompassing the following company names, divisions, and related entities:
Genmab Holding II B.V. and Genmab Finance LLC.
This list encompasses current and former names, alternate names, and key divisions associated with Genmab, ensuring you can easily find all relevant information under a single, unified profile.
